A little more than two years after in-licensing a pain drug from Grunenthal, Endo Pharmaceuticals said today that the treatment failed a mid-stage, placebo-controlled study for lower back pain. Endo said it would complete its analysis of the data on axomadol and then decide how it would proceed with the program. Endo release
Read the full article at FierceBiotech
